BioCentury
ARTICLE | Politics & Policy

China biopharma stocks fall after centralized tendering talks

September 12, 2018 11:41 PM UTC

Stocks of Chinese biopharma companies slid on Wednesday, possibly in response to a meeting Tuesday of China's National Medical Insurance Bureau on the centralized procurement of generics. Under centralized procurement, a single generic manufacturer would gain a 70% market share in 11 Chinese cities, according to a Chinese government news source.

Price cuts for generic versions of 33 listed drugs could range between 10-40% under the process, the source said. ...